3-122257279-C-G
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PS1PM1PM2PP2PP3PP5_Very_Strong
The NM_000388.4(CASR):c.384C>G(p.Phe128Leu) variant causes a missense change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Another nucleotide change resulting in the same amino acid substitution has been previously reported as Pathogenic in Lovd.
Frequency
Consequence
NM_000388.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 32
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Nephrolithiasis/nephrocalcinosis Pathogenic:1
The c.384C>G (p.F128L) alteration is located in exon 3 (coding exon 2) of the CASR gene. This alteration results from a C to G substitution at nucleotide position 384, causing the phenylalanine (F) at amino acid position 128 to be replaced by a leucine (L). Based on the supporting evidence, this alteration is pathogenic for CASR-related hypocalcemia; however, the association of this alteration with neonatal hyperparathyroidism/CASR-related hypocalciuric hypercalcemia is unknown. This variant was not reported in population-based cohorts in the Genome Aggregation Database (gnomAD). Two other alterations at the same codon, c.384C>A (p.F128L) and c.382T>C (p.F128L), have been detected in individuals with features consistent with CASR-related hypocalcemia (Pearce, 1996a; Raue, 2011) including one de novo occurrence (Ambry internal data). This amino acid position is highly conserved in available vertebrate species. Transient transfection of wildtype and CASR p.F128L mutant Ca2+ receptor (CaR) in HEK-293 cells demonstrated that CaR is active at lower concentrations of extracellular calcium in the mutant protein compared to wildtype, indicating gain of receptor function (Pearce, 1996b; Hauche, 2000). The in silico prediction for this alteration is inconclusive. Based on the available evidence, this alteration is classified as pathogenic. -
Autosomal dominant hypocalcemia 1;C1809471:Familial hypocalciuric hypercalcemia Pathogenic:1
This sequence change replaces phenylalanine, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 128 of the CASR protein (p.Phe128Leu). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with hypocalcemia and hypoparathyroidism (PMID: 8813042, 21645025). It has also been observed to segregate with disease in related individuals. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C15"). Experimental studies have shown that this missense change affects CASR function (PMID: 8813042, 8878438, 17284438). For these reasons, this variant has been classified as Pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
No publications associated with this variant yet.